Dosimetry of Radiopharmaceuticals for Diagnostic and Therapeutic Nuclear Medicine

摘要

A standard formalism for radionuclide internal radiation dosimetry was developed in the 1960s and continues to be refined today. Early work was based on a mathematical phantom but this is being replaced by phantoms developed from whole-body CT scans to give more realistic dose estimates. The largest contributors to the uncertainties in these dose estimates are the errors associated with in vivo activity quantitation, the variability of the biokinetics between patients and the limited information that can be obtained on these kinetics in individual patients. Despite these limitations, pre-treatment patient-specific dosimetry is being increasing used, particularly to limit the toxicity to non-target organs such as the bone marrow.